KR20070114197A - 씨피티를 억제하는 아미노부탄산의 유도체 - Google Patents

씨피티를 억제하는 아미노부탄산의 유도체 Download PDF

Info

Publication number
KR20070114197A
KR20070114197A KR1020077022098A KR20077022098A KR20070114197A KR 20070114197 A KR20070114197 A KR 20070114197A KR 1020077022098 A KR1020077022098 A KR 1020077022098A KR 20077022098 A KR20077022098 A KR 20077022098A KR 20070114197 A KR20070114197 A KR 20070114197A
Authority
KR
South Korea
Prior art keywords
amino
compound
methyl
tetradecyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077022098A
Other languages
English (en)
Korean (ko)
Inventor
파비오 기아네시
에마누엘라 타소니
마리아 오르넬라 틴티
로베르토 콘티
나탈리나 델워모
티지아나 브루네티
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20070114197A publication Critical patent/KR20070114197A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020077022098A 2005-03-02 2006-02-13 씨피티를 억제하는 아미노부탄산의 유도체 Ceased KR20070114197A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000090A ITRM20050090A1 (it) 2005-03-02 2005-03-02 Derivati dell'acido ammino-butanoico inibitore della cpt.
ITRM2005A000090 2005-03-02

Publications (1)

Publication Number Publication Date
KR20070114197A true KR20070114197A (ko) 2007-11-29

Family

ID=36090946

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077022098A Ceased KR20070114197A (ko) 2005-03-02 2006-02-13 씨피티를 억제하는 아미노부탄산의 유도체

Country Status (15)

Country Link
US (1) US20080161395A1 (enExample)
EP (1) EP1853556A1 (enExample)
JP (1) JP2008531613A (enExample)
KR (1) KR20070114197A (enExample)
CN (1) CN101133019A (enExample)
AR (1) AR052677A1 (enExample)
AU (1) AU2006220097B2 (enExample)
BR (1) BRPI0607558A2 (enExample)
CA (1) CA2599165A1 (enExample)
EA (1) EA200701868A1 (enExample)
IT (1) ITRM20050090A1 (enExample)
MX (1) MX2007009007A (enExample)
SG (1) SG159569A1 (enExample)
TW (1) TW200640842A (enExample)
WO (1) WO2006092204A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3144493A1 (en) * 2006-10-03 2008-04-10 Arbutus Biopharma Corporation Lipid containing formulations
CA2680366C (en) * 2007-03-09 2016-06-21 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
WO2009015485A1 (en) 2007-08-01 2009-02-05 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
WO2009132978A1 (en) * 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag 4-dimethylaminobutyric acid derivatives
CA2722114A1 (en) 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag 4-trimethylammonio-butyrates as cpt2 inhibitors
KR20230041744A (ko) * 2020-07-17 2023-03-24 사노피 파스퇴르 화학식 -nh-cx-a 또는 -nh-cx-nh-a의 적어도 하나의 말단 라디칼을 포함하는 지질 화합물, 이를 포함하는 조성물 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6822115B2 (en) * 1999-06-30 2004-11-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid
CA2680366C (en) 2007-03-09 2016-06-21 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer

Also Published As

Publication number Publication date
BRPI0607558A2 (pt) 2009-09-15
CN101133019A (zh) 2008-02-27
JP2008531613A (ja) 2008-08-14
ITRM20050090A1 (it) 2006-09-03
CA2599165A1 (en) 2006-09-08
AU2006220097A1 (en) 2006-09-08
US20080161395A1 (en) 2008-07-03
MX2007009007A (es) 2007-09-14
EP1853556A1 (en) 2007-11-14
AR052677A1 (es) 2007-03-28
EA200701868A1 (ru) 2008-02-28
TW200640842A (en) 2006-12-01
AU2006220097B2 (en) 2011-07-07
WO2006092204A1 (en) 2006-09-08
SG159569A1 (en) 2010-03-30

Similar Documents

Publication Publication Date Title
CN104262267B9 (zh) 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
US4897382A (en) Organic amide compounds derived from nitrogenous lipids
DE69809782T2 (de) Npy antagonisten
CA2658797A1 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
EP3889160B1 (en) Thiamine compound, preparation method and pharmaceutical composition thereof
US20050282871A1 (en) 3-(3,5-Disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors
US9518016B2 (en) Insulin secretion promoting agents
KR20240154590A (ko) Lpa 수용체 활성과 연관된 상태를 치료하기 위한 화합물 및 조성물
AU2006220097B2 (en) Derivatives of aminobutanoic acid inhibiting CPT
AU2010268666B2 (en) Fluorinated derivatives of 3-Hydroxypyridin-4-ones
HRP20090470A2 (hr) Sol 3-benzil-2-methil-2.3.3.a.4.5.6.7,7a-octahidrobenzo[d]isoksazol-4-ona
WO2024234619A1 (zh) 一种化合物的晶型、药物组合物及用途
US20160318892A1 (en) Prodrug compounds
US20190270698A1 (en) Compounds and methods for the treatment of neurodegenerative diseases
EP3964514A1 (en) Ginkgolide b derivative and salt thereof, preparation method therefor and use thereof
EP4512797A1 (en) Chiral aryl propionic acid derivative and pharmaceutical composition thereof, and use
US9255071B2 (en) Compounds having antibacterial activity, process for their preparation and pharmaceutical compositions comprising them
JP7595162B2 (ja) インデン誘導体プロドラッグの酸付加塩およびその製造方法｛ａｃｉｄ ａｄｄｉｔｉｏｎ ｓａｌｔ ｏｆ ｉｎｄｅｎｅ ｄｅｒｉｖａｔｉｖｅ ｐｒｏｄｒｕｇ ａｎｄ ｍｅｔｈｏｄ ｆｏｒ ｐｒｅｐａｒｉｎｇ ｓａｍｅ｝
EP3939976B1 (en) Prodrug of caspase inhibitor
HK1117821A (en) Derivatives of aminobutanoic acid inhibiting cpt
JP2008533122A (ja) 新規なチロシン誘導体
WO2026086905A1 (zh) 一种作为钠通道调节剂的化合物的前药及其用途
CN121627661A (zh) 一类2-硫-3-(哌啶烷二硫基)苯酞及其制备方法和用途
BR122025005591A2 (pt) Uso de e processo para preparação de derivados de ciclobutila 1,3-substituída, combinação farmacêutica, e kit
JP2011190257A (ja) 組織線維化疾患の予防または治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070927

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110113

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20121029

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130402

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20121029

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I